Canada markets closed

SMMT Jan 2025 1.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
5.300.00 (0.00%)
At close: 10:01AM EDT
Full screen
Previous Close5.30
Open5.30
Bid7.10
Ask7.80
Strike1.00
Expire Date2025-01-17
Day's Range5.30 - 5.30
Contract RangeN/A
Volume1
Open Interest691
  • Zacks

    Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

    Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.

  • Business Wire

    Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

    MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million.

  • Business Wire

    Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

    MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate